Morgan Stanley analyst Patrick Wood lowered the firm’s price target on Becton Dickinson to $280 from $310 and keeps an Overweight rating on the shares. A combination of rising 10 year rates and GLP-1 pressures have pushed the valuation of the U.S. MedTech sector down and given the material de-rating the firm is upgrading its Industry View on MedTech to Attractive, the analyst tells investors. Volumes remain in strong shape, capital equipment is looking healthy and the firm sees limited expected impact from GLP-1s, the analyst added in a note on the group in which the firm adjusted a number of price targets.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on BDX:
- Becton Dickinson reports FDA safety communication doesn’t impact BD syringes
- Becton Dickinson names Ronald Silverman chief medical officer
- Becton Dickinson earnings selloff a buying opportunity, says Barclays
- Becton Dickinson price target lowered to $280 from $305 at Piper Sandler
- Becton Dickinson sees FY24 adjusted EPS $12.70-$13.00, consensus $13.49